-
Lu Yinghao,et al
Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
-
Weng Kangqiang,et al
Identification of Treg-related prognostic molecular subtypes and individualized characteristics in clear cell renal cell carcinoma through single-cell transcriptomes and bulk RNA sequencing
-
Wu Sizhi,et al
Discovery of Momordin Ic that selectively reduces PD-L1 expression in multiple myeloma cells by recruiting SYVN1
-
Cen, S., Liu, K., Zheng, Y., Shan, J., Jing, C., Gao, J., Pan, H., Bai, Z., & Liu, Z.
BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer
-
Identification of a Hypoxia-Related Signature for Predicting Prognosis and the Immune Microenvironment in Bladder Cancer
-
Fu, Y., Peng, Y., Zhao, S., Mou, J., Zeng, L., Jiang, X., Yang, C., Huang, C., Li, Y., Lu, Y., Wu, M., Yang, Y., Kong, T., Lai, Q., Wu, Y., Yao, Y., Wang, Y., Gou, L., & Yang, J.
Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma. Frontiers in cell and developmental biology, 9, 689727.
-
Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report
-
Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis
-
Yan Yuhang,et al
Discovering New Metallo-Deubiquitinase CSN5 Inhibitors by a Non-Catalytic Activity Assay Platform
-
Li Shenghao,et al
PD-1/PD-L1 Interaction Upregulates YAP1 Expression in HepG2 Cells Through MAPK/ERK Pathway